Clinical trial
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or…
NCT00412022 · National Cancer Institute, Naples, Other · Unknown status
Key facts
| NCT number | NCT00412022 |
|---|---|
| Title | HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. |
| Official title | Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant… |
| Acronym | HOBOE |
| Lead sponsor | National Cancer Institute, Naples, Other |
| Collaborators | University of Campania Luigi Vanvitelli |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | tamoxifen, triptorelin, letrozole, zoledronic acid |
| Enrollment | 1,294 |
| Start date | Mar 1, 2004 |
| Primary completion | Nov 1, 2024 |
| Completion | Nov 1, 2024 |
| First posted | Dec 15, 2006 |
| Last update posted | Mar 24, 2023 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: